Fulcrum Therapeutics (FULC) Expected to Announce Earnings on Monday

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.01. On average, analysts expect Fulcrum Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fulcrum Therapeutics Trading Down 0.7 %

Shares of NASDAQ FULC traded down $0.04 during mid-day trading on Friday, reaching $5.37. 537,283 shares of the company's stock were exchanged, compared to its average volume of 970,910. Fulcrum Therapeutics has a twelve month low of $2.32 and a twelve month high of $10.13. The firm has a market capitalization of $289.87 million, a price-to-earnings ratio of -17.32 and a beta of 2.29. The business has a fifty day simple moving average of $3.38 and a 200 day simple moving average of $3.70.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "neutral" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, Fulcrum Therapeutics has a consensus rating of "Hold" and an average target price of $8.63.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.